Bexion Pharmaceuticals

About

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company based in Covington, Kentucky. The company is dedicated to developing innovative biologic therapies aimed at treating solid tumors and alleviating chemotherapy-induced peripheral neuropathy (CIPN). Its lead candidate, BXQ-350, is a first-in-class biologic that combines Saposin C with a phospholipid. This candidate has demonstrated a strong safety profile in multiple Phase 1 trials and shows promise in treating various cancers, including metastatic colorectal cancer, high-grade gliomas, and pediatric brain tumors. Bexion is focused on addressing unmet medical needs in oncology and neuropathic pain. The company is currently conducting clinical trials, including the Phase 1b/2 ASIST study for metastatic colorectal cancer and a proof-of-concept study for CIPN. Bexion has received support from The Michael J. Fox Foundation for its work on BXQ-350 in central nervous system disorders. With a small team of fewer than 25 employees, Bexion is led by experienced executives with backgrounds in major pharmaceutical companies.